Primary CNS Lymphoma Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Primary CNS Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

Primary CNS Lymphoma (PCNSL)
The Lymphoma Academic Research Organisation60 enrolled13 locationsNCT06931652
Recruiting
Phase 2

Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)Primary CNS Lymphoma (PCNSL)
Hyungwoo Cho12 enrolled1 locationNCT07062627
Recruiting
Not Applicable

Diagnosis; Objective RespOnse; THErApy

Primary CNS Lymphoma
IRCCS San Raffaele70 enrolled1 locationNCT05036564
Recruiting
Phase 2

NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL

Primary CNS Lymphoma (PCNSL)
NOBO Medicine33 enrolled10 locationsNCT06737250
Recruiting
Phase 2

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Primary CNS Lymphoma
Kim, Seok Jin30 enrolled1 locationNCT04627753
Recruiting

Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost

Primary CNS LymphomaBrain Lymphoma
Chang Gung Memorial Hospital36 enrolled1 locationNCT04006561
Recruiting
Phase 4

B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021

Diffuse Large B Cell LymphomaPrimary CNS LymphomaBurkitt Lymphoma+2 more
Federal Research Institute of Pediatric Hematology, Oncology and Immunology300 enrolled1 locationNCT05518383
Recruiting
Phase 2

RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

Primary CNS Lymphoma
National Research Center for Hematology, Russia30 enrolled1 locationNCT05425654